Abstract
We have previously shown that deficiency in the biotransformation enzyme glutathione-S-transferase theta (GSTT1) is a risk factor for multiple myeloma (MM). The present case-control study of 102 MM patients and 205 controls revealed a significant trend in increasing risk of MM with inheritance of multiple putative 'high risk' genetic variants in related pathways of benzene detoxification. Individuals who carried polymorphisms for GSTT1 null and/or high activity microsomal epoxide hydrolase (mEH 113YY+139HR or 113YY+139RR or 113YH+139RR) and/or low activity NAD(P)H:quinone oxidoreductase 1 (NQO1 187PS/SS) were 1.65, 2.49 and 13 times more likely to have MM (P(trend)=0.001).
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Benzene / metabolism
-
Case-Control Studies
-
Epoxide Hydrolases / genetics*
-
Epoxide Hydrolases / metabolism
-
Female
-
Genetic Predisposition to Disease*
-
Glutathione Transferase / genetics*
-
Glutathione Transferase / metabolism
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / enzymology
-
Multiple Myeloma / genetics*
-
NADH, NADPH Oxidoreductases / genetics*
-
NADH, NADPH Oxidoreductases / metabolism
-
Polymorphism, Single Nucleotide*
-
Risk Factors
Substances
-
NADH, NADPH Oxidoreductases
-
glutathione S-transferase T1
-
Glutathione Transferase
-
Epoxide Hydrolases
-
Benzene